Passage BIO (PASG) Operating Income (2019 - 2026)
Passage BIO (PASG) posted quarterly Operating Income of -$8.2 million for Q1 2026, up 49.89% year-over-year from -$5.5 million in Q1 2025, and up 40.45% quarter-over-quarter from -$13.8 million in Q4 2025.
Passage BIO (PASG) Operating Income (2019 - 2026) Analysis & Trends
Passage BIO's Operating Income history runs 8 years deep, the most recent figure standing at -$8.2 million for Q1 2026.
- In Q1 2026, Operating Income rose 49.89% year-over-year to -$8.2 million; the TTM figure through Mar 2026 stood at -$41.1 million (up 40.29% YoY), while the FY2025 annual figure was -$49.3 million, up 29.98% from the prior year.
- Operating Income for Q1 2026 stood at -$8.2 million, up from -$13.8 million in the prior quarter.
- The five-year high for Operating Income was -$8.2 million in Q1 2026, with the low at -$42.8 million in Q1 2022.
- The 5-year median for Operating Income is -$18.4 million (2023), against an average of -$22.0 million.
- The sharpest annual moves came in 2022 and 2025: Operating Income slipped 9.96% in 2022, then surged 58.19% in 2025.
- Passage BIO's Operating Income stood at -$28.2 million in 2022, then jumped by 34.69% to -$18.4 million in 2023, then increased by 22.64% to -$14.3 million in 2024, then grew by 2.96% to -$13.8 million in 2025, then surged by 40.45% to -$8.2 million in 2026.
- Business Quant data shows PASG's Operating Income at -$8.2 million in Q1 2026, -$13.8 million in Q4 2025, and -$8.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 133.12 Mn |
| 10 | Passage BIO | 13.96 Mn | 13.96 Mn | - | -8.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.27 Mn |
| Mar 31, 2026 | -8.25 Mn |
| Dec 31, 2025 | -13.85 Mn |
| Sep 30, 2025 | -8.66 Mn |
| Jun 30, 2025 | -10.33 Mn |
| Mar 31, 2025 | -16.46 Mn |
| Dec 31, 2024 | -14.27 Mn |
| Sep 30, 2024 | -20.70 Mn |
| Jun 30, 2024 | -17.38 Mn |
| Mar 31, 2024 | -18.05 Mn |
| Dec 31, 2023 | -18.45 Mn |
| Sep 30, 2023 | -28.67 Mn |
| Jun 30, 2023 | -25.39 Mn |
| Mar 31, 2023 | -35.88 Mn |
| Dec 31, 2022 | -28.24 Mn |
| Sep 30, 2022 | -27.53 Mn |
| Jun 30, 2022 | -39.81 Mn |
| Mar 31, 2022 | -42.81 Mn |
| Dec 31, 2021 | -51.16 Mn |
| Sep 30, 2021 | -47.10 Mn |